

1 **HIV Viral Non-Suppression and Its Associated Factors Among PMTCT Mothers Receiving**
2 **ARV Treatment in Ethiopia.**

3 **Belete Woldesemayat^{1*}, Ajanaw Yizengaw¹, Aschale Worku², Amelework Yilma¹, Sisay**
4 **Adane¹, Jaleta Bulti¹, Eleni Kidane¹, Gutema Bulti¹, Saro Abdella¹**

- 5
6 1. HIV AIDS and TB directorate, Ethiopian Public Health Institute, Addis Ababa, Ethiopia
7 2. Federal Ministry of Health, Addis Ababa, Ethiopia

8
9 *Corresponding author: beletewoldesemeyat@gmail.com, Ethiopian Public Health Institute, Arbegnoch
10 Street, Addis Ababa, Ethiopia. PoBox: 1242.

11

12

13

14

15

16

17

18

19

20

21 **Abstract**

22 **Background:** Pediatric HIV infection is mainly caused by Mother-to-child transmission (MTCT).
23 Without any effective medical intervention, 15-45% of infants born to HIV-positive women will
24 become infected with HIV. The contribution of viral non-suppression for MTCT is high. Hence,
25 this study was to determine the magnitude of HIV viral non-suppression, and associated factors
26 among PMTCT Mothers in Ethiopia.

27 **Methods:** The study was conducted from April 1, 2023, to December 31/ 2024 at 16 public health
28 facilities. An institutional-based cross-sectional study was employed and 496 HIV-positive
29 pregnant and lactating women on ART were included. Data was collected using a prechecked
30 questionnaire with paper mode and ODK (Open Data Kit) for each participant. Venous blood was
31 collected using two Ethylenediamine Tetra acetic Acid (EDTA) tubes for HIV viral load, CD4 and
32 Hgb test. HIV viral load tests were conducted at the EPHI (Ethiopian Public Health Institute)
33 National HIV reference laboratory using the COBAS 4800 System (Roche Molecular
34 Diagnostics). Data was edited and exported to SPSS from the ODK data file, and finally data
35 analysis was performed using SPSS version 26 software.

36 **Results:** 496 PMTCT Mothers were included in this study, the prevalence of HIV viral non-
37 suppression was 2.2% (95% CI; 1.1-3.9), the rate of viral detectability was 21.8 % (95% CI; 18.2-
38 25.7) and the rate of low-level viremia (LLV) was 9.1%. Family size ($X^2=7.20$; $p<0.001$), a poor
39 and fair level of Adherence ($X^2=18.553$; $p<0.001$), exposure to opportunistic infection ($X^2=25.29$;
40 $p<0.001$), survey time WHO clinical stages II & III ($X^2=25.29$; $p<0.001$), HIV status non-
41 disclosure other than Health care workers (HCWs) ($X^2=4.408$; $p=0.036$), and low survey time CD4

42 count (<350 cells/ul) ($X^2= 15.989$; $p<0.001$) were significantly associated to the rate of HIV viral
43 non-suppression.

44 **Conclusions:** In this study, HIV viral non-suppression among pregnant and lactating women is
45 relatively low (meet the UNAIDS 2030 target). However, Family size, level of Adherence,
46 exposure to opportunistic infection, WHO clinical stage level II and III, HIV status disclosure and
47 low CD4 count were significantly associated with the prevalence of viral non-suppression. To
48 achieve persistent HIV viral suppression enhanced adherence and counselling services should be
49 provided, tailored to the needs of the specific target group.

50

51

52 **Keywords:** Associated factors, PMTCT, HIV viral non-suppression, Low-level viremia

53 **1. Introduction**

54 Mother-to-child transmission (MTCT) of HIV is the primary mode of HIV infection in children
55 and paediatrics [1]. Without any effective medical intervention approximately 15–45% of
56 infants born from HIV-positive women will become infected with HIV, out of these about 5-
57 15% of them are got the infection with breastfeeding [2].

58 One of the biological risk factors of vertical transmission of HIV is related to the high maternal
59 viral burden, which is a significant predictor of transmission especially when an HIV viral load
60 of more than 1000 Ribonucleic Acid (RNA) copies per one millilitre of plasma [3-4]. In a
61 collaborative prospective study from seven European countries and the United States, MTCT
62 prevalence among anti-retroviral treated women with a viral RNA level of fewer than 1000
63 copies at close to delivery was only one percent (95% CI; 0.4%–1.9%) [5].

64 HIV viral load (VL) has a central role in determining MTCT risk, in addition to this; viral
65 lowering or suppression is strongly associated with decreased HIV disease progression, and
66 prevention of sexual transmission. Even if there is a limitation on PMTCT service coverage in
67 developing countries, viral suppression was registered after ART initiation in HIV-infected
68 pregnant women, particularly in sub-Saharan Africa [6]. The year between 2009 and 2014,
69 89% of infants were prevented with the provision of Anti-retroviral treatment (ART)
70 medication for pregnant and breastfeeding women in 21 high-priority sub-Saharan countries
71 [7].

72 HIV viral suppression is one of United Nations AIDS's (UNAIDS's) targets (95-95-95) to end
73 AIDS epidemics by 2030. The third 95 indicate that at least 95% of those on ART should be
74 virologically suppressed (<1000 RNA copies/ml), translating into a final target of at least 73%
75 and 86% of all PLWH (people living with HIV) achieving virologic suppression [8-9]. It will

76 enable a profound decrease in AIDS-related deaths by 2025 and substantially reduce infection
77 to near-zero levels by 2030 [10]. However, until now there are a lot of impediments, like
78 attitude and behavioural problems towards ART medication, physiological change (e.g.
79 pregnancy) and co-infection with infectious disease (e.g. Syphilis) to achieve the above
80 attainments [11].

81 On the other hand, different studies showed that because of different factors virological non-
82 suppression and drug resistance are more common in pregnant women than non-pregnant
83 mothers [12-14]. According to the Ethiopian national HIV/AIDS strategic plan, the main way
84 of MTCT is during breastfeeding, which 0.33% of infants were exposed because of the late
85 start of ART during pregnancy, 3.83% of cases were due to dropped off ART from 14,000
86 spectrum cases [15].

87 To achieve the optimal protection of MTCT of HIV, early identification (starting from the first
88 antenatal care visit) and during the postnatal period of viral non-suppression during pregnancy
89 and lactating period is very crucial. Many studies have reported on the HIV viral suppression
90 rate and associated factors among non-PMTCT Mothers populations, however, the magnitude
91 of HIV viral non-suppression in this study area and also limited study was reported in our
92 country. Therefore, this study aims to assess the magnitude of viral non-suppression and its
93 associated factors as programs aim for universal access among pregnant and lactating women
94 whose viral load level was non-suppressed in Ethiopia.

95

96 **2. Materials and Methods**

97 **2.1. Study design and area**

98 An institutional-based cross-sectional study was conducted from April 1/ 2023 to December
99 31/ 2023 in Addis Ababa, Ethiopia's capital city, located at 901'48"N 380 44'24"E/9.030000N
100 98.740000E. According to the Central Statistical Authority of Ethiopia in 2021 population
101 estimation, Addis Ababa has a total population of 3,774,000 people (1,782,000 male and
102 1,992,000 female), with an annual growth rate of about 2.4%. The city is located in the
103 country's heartland and is organized into 11 administrative sub-cities (Addis Ketema, Akaki
104 Kality, Arada, Bole, Gullele, Kirkos, Kolfie Keranio, Lideta, Niyasa Silk-lafto, Yeka and Lemi-
105 Kura). The health Bureau was in authority of the city's overall health activities. Numerous
106 clinics, health centres, and hospitals offer medical services [16]. According to Ethiopian Health
107 and Health Related Indicators, there were 78,106 anticipated pregnancies in Addis Ababa
108 and 105,086 delivered by a trained attendant [17].

109 **2.1. Study population**

110 All HIV-positive pregnant and lactating mothers, who have been taking ART for at least 6
111 months and were delivered or come to the health facility for Antenatal care (ANC) and or
112 postnatal care (PNC) services in Sixteen (16) selected health institutions in Addis Ababa and
113 given consent for data and sample collection were recruited in this study. Health facilities (HFs)
114 included in this study have been selected purposively based on their PMTCT client load. We
115 included 5 governmental hospitals, 10 health centres and 01 non-governmental health centre.
116 At the end of the 2022/23 budget year, the total number of PMTCT clients in Addis Ababa was
117 1041. A total of 16 health facilities were included in this study. Sample size determination was
118 estimated based on a single population proportion by considering different assumptions
119 including, the previous study conducted in West Shewa, Ethiopia, the proportion of viral non-

120 suppression was 11.3% [18] design effect 3, 95% confidence limit and 10% non-respondent
121 rate were considered. The final sample size was 510, and the data were collected from 496
122 participants in the study period.

123 **2.2. Data Collection**

124 Data was collected from 496 study participants by trained health professionals (1 laboratory
125 personnel and 1 nurse/health officer) from ANC and PNC clinics in the selected health
126 facilities. Additional training was given for data collectors on data collection using ODK,
127 laboratory sample collection, sample handling, and storage. Pre-checked questionnaires were
128 filled properly with ODK and paper forms. Sociodemographic (Age, Marital status, Education,
129 Employment status, Family size), clinical and behavioural determinants (Disclosure,
130 Adherence, WHO clinical stage, ART duration, ART regimen, CD4 count, HIV disclosure,
131 Use of memory aids, Use of alternative medicine, Use of alcohol and Substance abuse) and
132 Pregnancy-related variables (Gestational age, Parity, Anemic condition) variables were
133 collected properly. All CD4, Haemoglobin and Syphilis tests were performed during the survey
134 time by the previously existing referral system or in their facility laboratory. After the tests
135 were performed the result was entered and sent by ODK.

136 Ten (10) millilitre venous blood was collected by using two Ethylene diamine Tetra acetic acid
137 (EDTA) tubes and the plasma sample was separated and prepared immediately within 6 hours
138 of after sample collection according to sample collection and transportation guidelines and
139 stored 2-8 °C. All plasma samples were transported to the EPHI HIV national reference
140 laboratory within 5 days for HIV viral load testing. If the sample was not tested within 5 days
141 after collection, it was stored at -70 °C. Socio-demographic, clinical and other questionnaire-
142 based information was collected by trained nurses or health officers and sample collection,

143 preparation and storage was done by laboratory personnel. A supervisor does daily supervision
144 and sample transportation delegated from EPHI.

145 **2.3. Laboratory methods**

146 **HIV viral load**

147 Viral load testing was conducted at EPHI National HIV Reference Laboratory (NRHIVL)
148 using the Cobas 4800 system (Roche Molecular Diagnostics, Pleasanton CA, USA, 2016
149 Roche Molecular Systems, Inc.). In clinical specimens, the COBAS Real-Time HIV-1
150 Quantitative RT-PCR creates the amplified product from the HIV-1 RNA genome, in the
151 process of sample extraction the Cobas 4800 system uses QS (Quantification Standard), an
152 RNA sequence unrelated to the HIV-1 target sequence is added to each specimen. This
153 unrelated RNA sequence is amplified simultaneously with the target sequence by Real-time
154 polymerase chain reaction (RT-PCR) to ensure the sample preparation and amplification
155 procedures are working properly. Using fluorescent-labelled oligonucleotide probes, the
156 COBAS 4800 system analyzes the quantity of HIV-1 target sequence present during each
157 amplification cycle. The probes do not create a signal until they are directly connected to the
158 amplified product. The amplification cycle at which the 4800z detects fluorescence light is
159 proportional to the amount of HIV-1 RNA contained in the original sample. The COBAS 4800
160 RT system measures the quantity of HIV-1 target sequence present at each amplification cycle
161 using fluorescent-labeled oligonucleotide probes. The fluorescent signal recorded by the PCR
162 machine is proportional to the copies of the HIV-1 RNA concentration in the original sample
163 during the amplification cycle. We used a 0.4 millilitre (ml) sample volume, the lower detection
164 limit is 20 RNA copies per one ml of plasma [19].

165 **2.4. Operational definition**

166 **PMTCT Mothers:** Pregnant and lactating women who were taking ARV treatment in the
167 PMTCT clinics

168 **Viral non-suppression:** ≥ 1000 RNA copies/ml after ART treatment in the plasma sample

169 **Viral Detectability:** Viral load result ≥ 20 RNA copies/ml in the COBAS 4800 system

170 **Low-level viremia:** Viral load 50 to 999 RNA copies/ml

171 **Good Adherence:** Participants take medications at prescribed times and frequencies, and
172 follow restrictions regarding food and other medications at least 95%.

173 **Poor Adherence:** participants take medications at prescribed times and frequencies, and
174 follow restrictions regarding food and other medications less than 95%.

175 **2.5. Data processing and analysis**

176 Data was edited and entered into the computer using SPSS software version 26. The summary
177 of descriptive statistics for all dependent and independent variables was done with cross-
178 tabulation and Chi-square analysis. The association between quantitative variables associated
179 with the viral un-suppression was performed using Non-parametric Mann-Whitney U analysis,
180 P values were done and $P < 0.05$ was considered a significant association.

181 **2.6. Ethical Approval**

182 Ethical clearance was obtained from the Ethiopian Public Health Institute Scientific Ethical
183 Review Board with the protocol number EPHI-IRB-436-2022. Written informed consent was
184 taken from each study participant. The responders' personal information was kept private and
185 confidential except for the authors.

186

187 **3. Results**

188 **3.1. Socio-demographic characteristics of HIV positive Pregnant and** 189 **Lactating women**

190 In this study 496 participants were included from 16 health facilities; which comprised 5
191 hospitals, 10 governmental health centres and one non-governmental health centre. The total
192 response rate was 97.3%. Out of 496 participants, 265 (53.4%) were below the age of 30 years,
193 and the mean age of participants was 30.96 ± 5.24 (Standard deviation). 153 (30.8%) of
194 participant's educational status was primary school, 81 (16.3%) had no formal education and
195 74 (14.9%) of participants' educational status was college or university. The majority of
196 participants, 427 (86.1%) were Married, 384 (77.4%) were Orthodox Christians, 273 (55%)
197 were housewives and many participants, 285 (57.5%) had family sizes were 3-4 (**Table 1**).

198 **3.2. Clinical and Behavioral Characteristics of Study Participants**

199 Among 496 participants 138 (27.8%) had discordant HIV results, whereas almost half of the
200 participants 244 (49.2%) had the same result (HIV-positive) with their partners. The majority,
201 455 (91.7%) of participants received regular ART supplies for the last 6 months. Similarly, 465
202 (93.8%), 461 (92.9%), and 443 (89.3%) participants had good adherence, WHO clinical stage
203 I and had not used any alcohol or other substance for the last month respectively. Out of 496
204 subjects, 304 (61.3%) had a habit of using memory aid to take ART medicine. On the other
205 hand, among 356 participants who were receiving previous ART regimens the majority, 320
206 (89.9%) were receiving TDF + 3TC + EFV (**Table 2**).

207

208 In this study for the last 6 months 211 (42.5%) of participants were skipping/stopping ARV
209 medication once or more than once. Out of these 211 participants, 82 (16.5%) skipped/stopped
210 their medication due to they forgot/busy. Similarly, 0.8%, 3.6%, 0.4 %, and 2% skipped/missed

211 their medication because of taking herbal medicines, hospital admission and faith healing
212 respectively (**Figure 1**). According to Figure 2, 455 (91.7%) participants received the new
213 DTG-based ART regimen (TDF, 3TC, DTG). Whereas, 17 (3.4%), 8 (1.6%) and 7 (1.4%)
214 participants were taking ART drugs including, TDF + 3TC + ATV/r, ABC+ 3TC + LPV/r, and
215 TDF + 3TC + EFV respectively. 32 (6.5%) of ART patients were receiving a second-line
216 regimen and the rest 464 (93.5%) were taking a first-line treatment regimen (**Figure 2**).

217
218 According to the obstetrics characteristics of study participants, 320 (64.5%) were lactating
219 women and the rest 176 (35.5%) were HIV-positive pregnant women. Among pregnant
220 women, 11 (6.3%) were in the first trimester and 84 (47.7%) were in the third trimester. 194
221 (39.1%) of participants had their pregnancy for the first time (primigravida). The majority of
222 participants had 0-1 child (73%), did not have any types of chronic illness (98.2%), had good
223 MUAC measurement (95.4%), ≥ 350 CD4 cells/ul (93.3%) and a negative syphilis antibody
224 test (97.2%) (**Table 3**).

225 **3.3. Prevalence of HIV-1 viral non-suppression, viral undetectability and** 226 **low-level viremia**

227 Among 496 HIV-infected pregnant and lactating women who are receiving ART, 11 (2.2%;
228 95% CI; 1.1 – 3.9) had virologically not suppressed (HIV VL \geq 1000 copies/ml). The remaining
229 485 (97.8%) study participants had successfully suppressed viral load (**Figure 3A**). In this
230 study, the magnitude of viral undetectability was 21.8 % (95% CI; 18.2-25.7) (**Figure 3B**). All
231 participants taking first-line or second-line ARV treatment during the survey time were
232 included. The low-level viremia (LLV) (50-999 RNA copies/ml) magnitude of this study was
233 9.1% (45/496). Participants whose viral load was from 20-50 RNA copies/ml were 52 (10.5%)
234 (**Figure 4**).

235 **3.4. Associated factors of HIV-1 viral non-suppression**

236 To determine the associated risk factors of HIV-1 viral non-suppression among pregnant and
237 lactating women who were receiving option B+ in the PMTC department in Addis Ababa
238 Health facilities. Socio-demographic, clinical, behavioural, nutritional, obstetric, and
239 immunological determinants were included. To determine the socio-demographic risk factors
240 for the viral non-suppression group among the participants, except family size, all independent
241 variables including; age, marital status, type of health facility, educational status, religious view
242 and occupational status were not significantly associated with non-viral suppression.
243 Regarding family size the proportion of HIV-1 viral non-suppression was high who had a high
244 family size (>4) and according to chi-square analysis the family size is significantly associated
245 with non-viral suppression ($X^2=7.20$; $P=0.027$).

246 Regarding clinical and behavioural risk factors, participants who had poor adherence and fair
247 adherence were found high proportion of viral non-suppression, poor 1(9.1%) Fair 3(15.0 %),
248 the chi-square analysis showed that Adherence was significantly associated with viral non-
249 suppression ($X^2=18.553$; $p<0.001$). Opportunistic infections during the survey time were
250 significantly associated with viral non-suppression ($X^2=25.290$; $P<0.001$). WHO clinical stage
251 II and III had a high proportion of viral non-suppression (14.3%) compared to WHO clinical
252 stage I (1.3%), the chi-square test also showed that significantly associated with viral non-
253 suppression ($X^2=25.29$; $P<0.001$). Similarly, participants who didn't disclose their HIV status
254 other than HCWs were one of the associated factors for HIV-1 viral non-suppression ($X^2=$
255 4.408 ; $P=0.036$).

256 The rate of viral non-suppression in patients whose CD4 count was less than 350 cells/ul was
257 12.1%, whereas the rate of viral non-suppression among those whose CD4 count ≥ 350 cells/ul
258 in the survey time was 1.5%. Therefore the chi-square analysis showed that CD4 count is
259 significantly associated with HIV-1 viral non-suppression ($X^2=15.989$; $P<0.001$) (**Table 4**).

260 According to Figure 5, 211 (42.5%) participants skipped/missed their ARV medications at least
261 once in the last 6 months. 6 (3%) of those HIV-1 viral loads were ≥ 1000 RNA copies/ml, while
262 the rest of the viral suppression among these patients was 97% (n=205). Being forgotten/busy,
263 running out of pills, depression, food shortage, and feeling better have had some associations
264 with the rate of viral non-suppression. However, based on logistic regression analysis the
265 associations were not reached at the significant level ($p > 0.05$) (**Figure 5**).

266 According to independent T-test analysis, except for CD4 T cells, all the other parameters
267 (Hgb, MUAC, Age and duration on ART) were not statistically significant association with
268 HIV-1 viral non-suppression. The mean value of CD4 T cell count in the viral non-suppression
269 group was 427 cells/ul and in the suppressed group was 557.85 cells/ul which indicated that
270 the non-suppressed group CD4 is significantly lower compared to the suppressed group
271 ($P=0.013$)(**Figure 6**). Similarly, the non-parametric Mann-Whitney U analysis showed that
272 only CD4 T cells are significantly associated with HIV-1 Viral non-suppression (**Table 5**).

273

274

275

276

277

278

279

280 **4. Discussion**

281 HIV viral non-suppression is a key factor for HIV transmission through vertically or
282 horizontally. The risk of transmission is null to very low if the HIV viral suppression is
283 successful for people who are taking ARV medication. So, to create an AIDS-free generation
284 monitoring viral suppression, enhanced Adherence and counselling in ART drugs, early case
285 detections are the main issues in HIV/AIDS control and prevention programs. Moreover, in
286 HIV-infected women who are taking ARV treatment and could maintain their HIV-1 viral load
287 <1000 RNA copies/ml in pregnancy, delivery and breastfeeding, the mother-to-child HIV
288 transmission could be very low (<1%). Similarly, if their viral load is maintained undetectable
289 throughout their PMTCT period the vertical transmission is almost zero [20]. Our study
290 evaluated the magnitude of HIV-1 Viral non-suppression and associated factors among HIV-
291 positive pregnant and lactating women who are taking ARV treatment for at least six months.

292 In this study, the prevalence of HIV-1 viral non-suppression was 2.2 % (95% CI; 1.1-3.9), viral
293 detectability was 21.8 % (95% CI; 18.2-25.7) and the magnitude of low-level viremia (LLV)
294 (50-999 RNA copies/ml) was 9.1%. This result is in line with the study conducted in Northern
295 Ethiopia, where the rate of viral non-suppression among pregnant women was 1.31% [21], and
296 a study reported from South Africa, showed that viral non-suppression among women on ART
297 was 4.1% [21]. Similarly, in another study from Northeastern South Africa, the rate of low-
298 level viremia was quite similar to our study (13.8%) [23]. Also, the prevalence of detectable
299 viral load was reported as 17.3 % in Malawi [24]. On the contrary, many previous studies
300 showed that the prevalence of viral non-suppression among pregnant and lactating women was
301 high including in, the Amhara region, Ethiopia (9.1%) [25], Rural South Africa (14.7%) [23],
302 Rural Uganda (19%) [26], Southern and Central Malawi (16%) [27], Mazowe, Zimbabwe
303 (5.6%) [28], Malawi (13.5%) [29], and 12.1% study from Kenya [30]. Our study showed that

304 the prevalence of HIV-1 viral non-suppression is comparatively low, it may mainly be related
305 to the follow-up of PMTCT women increased due to their obstetrics conditions and access to
306 PMTCT service expansion. Additionally, other differences including; type of population,
307 adherence level of the population, geographical and cultural differences and some studies that
308 include ART naïve participants might be the reason for high viral non-suppression. Viral load
309 monitoring programs in the country among PMTCT clients may have a huge impact on viral
310 load suppression, the local health system and program focus could affect the suppression rate
311 [31]. Even though, the prevalence of low viral non-suppression was recorded, it had a critical
312 impact on the program as well as for the offspring since HIV transmission is very high, the
313 recent cohort study result also showed that the risk of HIV transmission was nine times more
314 likely to transmit to the baby if the viral load result is non-suppressed in the time of pregnancy
315 or breastfeeding [32].

316 Pregnant and lactating mothers whose HIV viral non-suppression was significantly associated
317 with the level of Adherence, presence of opportunistic infection, HIV status disclosure status,
318 family size and CD4 count. These results are supported by many studies which were performed
319 in Ethiopia as well as in different regions of the world. In this study, poor level of adherence
320 and fair level of adherence showed a high proportion of non-viral suppression (14.8%;
321 $X^2=18.55$; $P= <0.001$), a significantly high proportion of non-viral suppression among poor
322 adherence also reported from Amhara region, Ethiopia [25] and Kenya [30]. Exposure to
323 opportunistic infection was one of the associated factors for HIV viral non-suppression in this
324 study, which is in line with the results reported from Uganda [33] and Ethiopia [34], even
325 though both studies were performed on all Adult HIV patients who were taking ART.

326 The other important factor which is associated with viral non-suppression is the disclosure
327 status of HIV other than health care workers, the proportion of non-disclosure groups is
328 significantly high (4.5%; $X^2=4.41$; $p=0.036$) compared to participants who disclosed those HIV

329 positivity statuses, this result was concordant with the study conducted in Uganda [26] and
330 Kenya [30]. On the other hand, some studies indicated that disclosure status was not
331 significantly associated with the prevalence of non-viral suppression [23, 35]. This difference
332 might be related to cultural differences of the study population, for example, our study
333 population had little or no habit of disclosing their result other than health care workers due to
334 fright of discrimination. It leads to they might not taking their ARV medication to hide
335 themselves from others. In a similar context, this study also revealed that the high numbers of
336 family size (>4 people in the family) was significantly associated (high proportion of viral non-
337 suppression among these women) with viral non-suppression (4.5%; $X^2 = 7.20$; $p < 0.001$). The
338 reason for this association might be related to the nutritional status of participants, even if this
339 study showed that the MUAC measurement association did not reach the significant level with
340 the viral non-suppression. In low-income countries high family size is significantly association
341 with poverty and malnutrition [36].

342 In this study, CD4 count <350 cells/ul in the survey time was significantly associated with the
343 HIV viral non-suppression (12.1 %, $X^2 = 15.989$; $p < 0.001$) and the Non-parametric Mann-
344 Whitney U analysis also showed that the viral non-suppression was significantly associated
345 with low CD4 count ($p = 0.013$). This result was concordant with the study in Northern Ethiopia,
346 specifically CD4 count in survey time (< 200 cells/ul) was significantly associated with viral
347 non-suppression [21]. On the other hand, the result reported in Uganda that baseline CD4 count
348 was not associated with non-viral suppression [37]. The difference is related to the time of CD4
349 cell count because after ART treatment CD4 count could be reversed.

350 In our study the other factor associated with HIV viral non-suppression was the WHO clinical
351 stage of participants in survey time, the result showed that participants in clinical stage II and
352 Stage III had a statistically significant association with viral non-suppression. 14.3% of
353 participants who were in WHO clinical stages II and III were virally non-suppressed (≥ 1000

354 RNA copies/ml) ($X^2= 25.29$; $p<0.001$). In this study, there were no WHO clinical stage IV
355 participants. This result is supported by the study conducted in Ethiopia [25]. According to
356 different studies throughout the World HIV/AIDS disease progression, HIV viral replication
357 and immune suppression (low CD4 count) had closely related outcomes [27, 38]. This study
358 has some limitations including; Since it was an institution-based study we might not have
359 included persons who had poor adherence to ARV drugs due to they had not any follow-up in
360 the data collection period.

361 **5. Conclusion**

362 This study revealed that the prevalence of HIV viral non-suppression among pregnant and
363 lactating women is relatively low and it showed that meeting the UNAIDS 2030 target. This
364 performance might be related to the HIV prevention and control program implementation,
365 specifically the PMTCT service improvement from time to time in pregnant and lactating
366 women to prevent HIV transmission risks to their children. However, in this study Family size,
367 level of Adherence, exposure to opportunistic infection, WHO clinical stage level II and III,
368 HIV status disclosure and low CD4 value were significantly associated with the prevalence of
369 viral non-suppression. Even though the prevalence rate was low, enhanced Adherence and
370 counselling should be increased for specific groups of pregnant and lactating women like;
371 women who have large family sizes and do not disclose their HIV status to immediate family
372 members to achieve persistent HIV viral suppression.

373 **Acknowledgements**

374 Our acknowledgement is forwarded to all staff of the Ethiopian Public Health Institute, the
375 national HIV reference laboratory for valuable support for sample handling and laboratory
376 analysis.

377 **Funding**

378 This research received no specific grant from any funding institutions.

379 **Author Contributions**

380 **Conceptualization:** Belete Woldesemayat

381 **Data curation:** Belete Woldesemayat, Ajanaw Yizengaw

382 **Formal analysis:** Belete Woldesemayat, Ajanaw Yizengaw

383 **Investigation:** Amelework Yilma, Sisay Adane, Eleni Kidane

384 **Methodology:** Amelework Yilma, Sisay Adane, Gutema Bulti

385 **Resources:** Jaleta Bulti, Saro Abdella

386 **Supervision:** Belete Woldesemayat

387 **Validation:** Saro Abdella

388 **Visualization:** Belete Woldesemayat, Ajanaw Yizengaw

389 **Writing – original draft:** Belete Woldesemayat, Aschale Worku

390 **Writing–review & editing:** Belete Woldesemayat, Ajanaw Yizengaw, Aschale Worku,
391 Amelework Yilma, Sisay Adane, Eleni Kidane, Gutema Bulti, Jaleta Bulti, Saro Abdella,. All
392 authors have read and agreed to the published version of the manuscript.

393

394

395

396

397

398 Reference

- 399 1. Bucagu M, Bizimana J de D, Muganda J, Humblet CP. Socio-economic, clinical and
400 biological risk factors for mother - to – child transmission of HIV-1 in Muhima health
401 centre (Rwanda): a prospective cohort study. Arch Public Heal. 2013;71(4):1–12.
- 402 2. World Health Organization. Global guidance on criteria and processes for validation:
403 elimination of mother-to-child transmission of HIV and syphilis. World Health
404 Organization; 2017.
- 405 3. Plaeger S, Bermudez S, Mikiyas Y, Harawa N, Dickover R, Mark D, et al. Decreased
406 CD8 Cell-Mediated Viral Suppression and Other Immunologic Characteristics of
407 Women Who Transmit Human Immunodeficiency Virus to Their Infants. J Infect Dis.
408 1999;179(6):1388–94.
- 409 4. Fischetti L, Danso K, Dompok A, Addo V, Haaheim L, Allain JP. Vertical
410 transmission of HIV in Ghanaian women diagnosed in cord blood and post-natal
411 samples. J Med Virol. 2005;77(3):351–9.
- 412 5. Ioannidis JP, Abrams EJ, Ammann A, Bulterys M, Goedert JJ, Gray L, et al.
413 Perinatal Transmission of Human Immunodeficiency Virus Type 1 by Pregnant
414 Women with RNA Virus Loads <1000 Copies/mL. J Infect Dis. 2001;183(4):539–45.
- 415 6. Myer L, Phillips T, Ramjith J, Bekker LG, McIntyre JA, Abrams EJ. Viral suppression
416 after antiretroviral therapy initiation in pregnancy in South Africa. In Abstract
417 presented at the Conference on Retroviruses and Opportunistic Infections 2015 (pp. 23-
418 26).
- 419 7. UNAIDS M. Progress report on the global plan. Towards the elimination of new HIV
420 infections among children by. 2015. Available from:
421 [http://www.unaids.org/sites/default/files/media_asset/JC2774_2015ProgressReport_G](http://www.unaids.org/sites/default/files/media_asset/JC2774_2015ProgressReport_GlobalPlan_en.pdf)
422 [lobalPlan_en.pdf](http://www.unaids.org/sites/default/files/media_asset/JC2774_2015ProgressReport_GlobalPlan_en.pdf)

- 423 8. Lima VD, St-Jean M, Rozada I, Shoveller JA, Nosyk B, Hogg RS, et al. Progress
424 towards the United Nations 90-90-90 and 95-95-95 targets: The experience in British
425 Columbia, Canada. *J Int AIDS Soc.* 2017;20(3):1–9.
- 426 9. World Health Organization. Global action plan on HIV drug resistance 2017-2021:
427 2018 progress report, July 2018: executive summary. World Health Organization;
428 2018.
- 429 10. Dunaway K, Brion S, Hale F, Alesi J, Assan H, Chung C, et al. What will it take to
430 achieve the sexual and reproductive health and rights of women living with HIV?
431 *Women’s Heal.* 2022;18. <https://doi.org/10.1177/1745505722108036>.
- 432 11. Petty LA, Steinbeck JL, Pursell K, Jensen DM. Human immunodeficiency virus and
433 coinfection with hepatitis B and C. *Infect Dis Clin North Am.* 2014 Sep;28(3):477-99.
434 doi: 10.1016/j.idc.2014.05.005. PMID: 25151567.
- 435 12. Kingoo JM. HIV Treatment Failure Markers; Virologic Outcomes after 12 Months of
436 Antiretroviral Therapy among Patients Receiving HAART in Busia County, Kenya
437 (Doctoral dissertation, JKUAT-COPAS).
- 438 13. Read JS, Cohen RA, Hance LF, MacHado ES, Mussi-Pinhata MM, Ceriotto M, et al.
439 Missed opportunities for prevention of mother-to-child transmission of HIV-1 in the
440 NISDI Perinatal and LILAC cohorts. *Int J Gynecol Obstet.* 2012;119(1):70–5.
- 441 14. Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al.
442 Factors Associated with Virological Non-suppression among HIV-Positive Patients on
443 Antiretroviral Therapy in Uganda, August 2014-July 2015. *BMC Infect Dis.*
444 2017;17(1):1–11.
- 445 15. (FHAPCO) FH prevention and control office. HIV/AIDS National Strategic Plan (NSP)
446 for Ethiopia 2021-2025. 2021.

- 447 16. CSA. Population Size of Towns by Sex, Region, Zone and Weredas as of July 2021.
448 Cent Stat Auth Ethiop. 2021.
- 449 17. Ethiopian Public Health Institute (EPHI) [Ethiopia]. Mini Demographic and Health
450 Survey: key indicators [Internet]. Handbook of Federal Countries, 2005. 2019. 136–
451 148 p. Available from: www.DHSprogram.com.
- 452 18. Demissie DB, Bulto GA, Mekuria WT, Dufera FN, Gamshe EN. Evaluation of
453 antiretroviral therapy initiated among pregnant women under option B+ by viral load
454 and CD4 count outcomes in selected hospitals of West Shewa Zone, Oromia Region,
455 Ethiopia. HIV/AIDS-Research and Palliative Care. 2020 Mar 19:127-34.
- 456 19. World Health Organization. WHO Prequalification of In Vitro Diagnostics Public
457 Report Product: cobas HIV-1 Quantitative nucleic acid test for use on the cobas 4800
458 System. 2021. 1–65 p.
- 459 20. World Health Organization policy brief. The role of HIV viral suppression in improving
460 individual health and reducing transmission: policy brief. Geneva: World Health
461 Organization; 2023. Who. 2023;(ISBN 978-92-4-005517-9 (electronic version)):16.
- 462 21. Desta AA, Woldearegay TW, Futwi N, Gebrehiwot GT, Gebru GG, Berhe AA, et al.
463 HIV virological non-suppression and factors associated with non-suppression among
464 adolescents and adults on antiretroviral therapy in northern Ethiopia: A retrospective
465 study. BMC Infect Dis. 2020;20(4):<https://doi.org/10.1186/s12879-019-4732-6>.
- 466 22. Ntombela NP, Kharsany AB, Soogun A, Yende-Zuma N, Baxter C, Kohler HP,
467 McKinnon LR. Viral suppression among pregnant adolescents and women living with
468 HIV in rural KwaZulu-Natal, South Africa: A cross-sectional study to assess progress
469 towards UNAIDS indicators and Implications for HIV Epidemic Control. Reproductive
470 Health. 2022;19(1):116.

- 471 23. Ngandu NK, Lombard CJ, Mbira TE, Puren A, Waitt C, Prendergast AJ, et al. HIV viral
472 load non-suppression and associated factors among pregnant and postpartum women in
473 rural northeastern South Africa: A cross-sectional survey. *BMJ Open*. 2022;12(3):1–
474 12.
- 475 24. Chagomerana MB, Miller WC, Tang JH, Hoffman IF, Harrington BJ, DiPrete B, Wallie
476 S, Jumbe A, Limarzi L, Hosseinipour MC. Prevalence of antiretroviral therapy
477 treatment failure among HIV-infected pregnant women at first antenatal care: PMTCT
478 Option B+ in Malawi. *PLoS One*. 2018;13(12):e0209052.
- 479 25. Endalamaw Alamneh D, Shiferaw MB, Demissie MG, Emiru MA, Kassie TZ, Lakew
480 KE, et al. Virological Outcomes Among Pregnant Women Receiving Antiretroviral
481 Treatment in the Amhara Region, North West Ethiopia. *HIV/AIDS - Res Palliat Care*.
482 2023;15:209–16.
- 483 26. Koss CA, Natureeba P, Kwarisiima D, Ogena M, Clark TD, Olwoch P, et al. Viral
484 suppression and retention in care up to 5 years after initiation of lifelong art during
485 pregnancy (option b+) in rural Uganda. *J Acquir Immune Defic Syndr*.
486 2017;74(3):279–84.
- 487 27. Hosseinipour M, Nelson JAE, Trapence C, Rutstein SE, Kasende F, Kayoyo V, et al.
488 Viral suppression and HIV drug resistance at 6 months among women in Malawi’s
489 option B+ program: Results from the PURE Malawi study. *J Acquir Immune Defic*
490 *Syndr*. 2017;75(2):S149–55.
- 491 28. Nyakura J, Shewade HD, Ade S, Mushavi A, Mukungunugwa SH, Chimwaza A, et al.
492 Viral load testing among women on ‘option B+’ in Mazowe, Zimbabwe: How well are
493 we doing? *PLoS One*. 2019;14(12):1–14.
- 494 29. Chagomerana MB, Edwards JK, Zalla LC, Carbone NB, Banda GT, Mofolo IA, et al.
495 Timing of HIV testing among pregnant and breastfeeding women and risk of mother-

- 496 to-child HIV transmission in Malawi: a sampling-based cohort study. *J Int AIDS Soc.*
497 2021;24(3):e25687.
- 498 30. Chohan BH, Ronen K, Khasimwa B, Matemo D, Osborn L, Unger JA, Drake AL, Beck
499 IA, Frenkel LM, Kinuthia J, John-Stewart G. Food insecurity, drug resistance and non-
500 disclosure are associated with virologic non-suppression among HIV pregnant women
501 on antiretroviral treatment. *PloS one.* 2021;16(8):e0256249.
- 502 31. Myer L, Essajee S, Broyles LN, Watts DH, Lesosky M, El-Sadr WM, et al. Pregnant
503 and breastfeeding women: A priority population for HIV viral load monitoring. *PLoS*
504 *Med.* 2017;14(8):1–7.
- 505 32. Duri K, Mataramvura H, Chandiwana P, Mazhandu AJ. Mother-to-Child Transmission
506 of HIV Within 24 Months After Delivery in Women Initiating Lifelong Antiretroviral
507 Therapy Pre / Post-Conception or Postnatally ; Effects of Adolescent Girl and Young
508 Woman Status and Plasma Viremia Late in Pregnancy. *Front Virol.* 2022;2(906271).
509 10.3389/fviro.2022.906271.
- 510 33. Gordon TP, Talbert M, Mugisha MK, Herbert AE. Factors associated with HIV viral
511 suppression among adolescents in Kabale district, South Western Uganda. *Plos one.*
512 2022;17(8):e0270855.
- 513 34. Erjino E, Abera ELTD. Time to Viral Load Suppression and Its Predictors Among
514 Adult Patients on Antiretro Viral Therapy in Nigist Eleni Mohammed Memorial
515 Comprehensive. *HIV/AIDS - Res Palliat Care.* 2023;15
516 (<https://doi.org/10.2147/HIV.S408565>):157–71.
- 517 35. Napyo A, Tumwine JK, Mukunya D, Tumuhamyé J, Arach AAO, Ndeezi G, et al.
518 Detectable HIV-RNA Viral Load Among HIV-Infected Pregnant Women on Treatment
519 in Northern Uganda. *Int J Matern Child Heal AIDS.* 2020;9(2):232–41.

- 520 36. Ajao KO, Ojofeitimi EO, Adebayo AA, Fatusi AO, Afolabi OT. Influence of family
521 size, household food security status, and child care practices on the nutritional status of
522 under-five children in Ile-Ife, Nigeria. African journal of reproductive health.
523 2010;14(4).
- 524 37. Atuhaire P, Matovu F, Nakalega R, Kataike H, Nabwana M, Lukyamuzi Z, Guwattude
525 D. Time to first viral load testing among pregnant women living with HIV initiated on
526 option B+ at 5 government clinics in Kampala city, Uganda: Retrospective cohort
527 study. International Journal of Infectious Diseases. 2021;104:526-31.
- 528 38. Langford SE, Ananworanich J, Cooper DA. AIDS Research and Therapy Predictors
529 of disease progression in HIV infection : a review. AIDS Res Ther. 2007;4(11).
530 10.1186/1742-6405-4-11.
- 531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546

547 **Tables and figures**

548

549 **Tables**

550 **Table 1: Socio-demographic characteristics of HIV-positive receiving ART drugs among**
 551 **pregnant and lactating women.**

Variables	Category	Frequency	Percent
Age group	<30 years	265	53.4
	>=30 years	231	46.6
Educational status	No formal education	81	16.3
	Primary School	188	37.9
	Secondary School	153	30.8
	College/ University	74	14.9
Marital Status	Divorced	29	5.8
	Widowed	9	1.8
	Married	427	86.1
	Single	31	6.3
Religious Belief	Orthodox Christian	384	77.4
	Protestant	44	8.9
	Muslim	62	12.5
	Others	6	1.2
Occupational Status	Government and private employee	144	29.0
	Housewife	273	55.0
	Merchant	31	6.3
	Unemployed	36	7.3
	Others	12	2.4
Type of health facility	Health Centre	332	66.9
	Hospital	164	33.1
Family size	1-2	78	15.7
	3-4	285	57.5
	> 4	133	26.8

552

553

554

555

556

557 **Table 2: Clinical and Behavioural characteristics of PMICT Mothers**

Variables	Category	Frequency	Percent
Partner’s HIV status	Negative	138	27.8
	Positive	244	49.2
	Unknown	114	23.0
Receiving regular supplies of ART	No	41	8.3
	Yes	455	91.7
Level of Adherence	Poor	11	2.2
	Fair	20	4.0
	Good	465	93.8
Opportunistic infection exposed	No	461	92.9
	Yes	35	7.1
WHO clinical stage	Stage III	11	2.2
	Stage II	24	4.8
	Stage I	461	92.9
Alcohol /substance use in the last one month	No	443	89.3
	Yes	53	10.7
HIV status disclosure other than HCWs	No	133	26.8
	Yes	363	73.2
The habit of using a memory aid	No	192	38.7
	Yes	304	61.3
Previous ART regimen (n=356)	1B	2	0.6
	1C (AZT + 3TC + NVP)	34	9.6
	1E (TDF + 3TC + EFV)	320	89.9
ART duration	6-11 months	53	10.7
	1 to 5 years	175	35.3
	5 to 10 years	165	33.3
	more than 10 years	103	20.8

558
559
560
561
562
563
564
565
566
567
568
569
570

571 **Table 3: Obstetrics characteristics of PMTCT Mothers**

Variables	Category	Frequency	Percent
Type of participants	Pregnant	176	35.5
	Lactating	320	64.5
Gestational Age (n=176)	First Trimester	11	6.3
	Second Trimester	81	46.0
	Third Trimester	84	47.7
Gravidity	Primigravida	194	39.1
	Multigravida	302	60.9
Parity	0-1 child	362	73.0
	>=2 child	134	27.0
Chronic Illness (at the time of the survey)	No	487	98.2
	Yes	9	1.8
MUAC	<23 cm	23	4.6
	>=23 cm	473	95.4
CD4 (time of survey)	<350 cells/ul	33	6.7
	>=350	463	93.3
Syphilis Antibody test	Positive	14	2.8
	Negative	482	97.2

572

573

574 **Table 4: Chi-square analysis of factors associated with HIV-1 viral non-suppression**
 575 **among PMTCT Mothers.**

Variables	Category	Viral non-suppressed N (%)	Viral suppressed N (%)	Chi-square (X ²)	P- value
Type of health facility	Health Centre	6 (1.8)	326 (98.2)	0.780	0.377
	Hospital	5 (3.0)	159 (97.0)		
Age	<30 years	4 (1.5)	261 (98.5)	1.316	0.251
	>=30 years	7 (3.0)	224 (97.0)		
Educational status	No formal education	4 (4.9)	77 (95.1)	3.765	0.288
	Primary School	3 (1.6)	185 (98.4)		
	Secondary School	2 (1.3)	151 (98.7)		
	College/ University	2 (2.7)	72 (97.3)		
Marital Status	Divorced	2 (6.9)	27 (93.1)	3.510	0.319
	Widowed	0 (0.0)	9 (100.0)		
	Married	8 (1.9)	419 (98.1)		
	Single	1(3.2)	30 (96.8)		
Religious Belief	Orthodox Christian	9 (2.3)	375 (97.7)	0.269	0.966
	Protestant	1 (2.3)	43 (97.7)		
	Muslim	1 (1.6)	61 (98.4)		
	Others	0 (0.0)	6 (100.0)		
Occupational Status	Government and private employee	3 (2.1)	141 (97.9)	5.409	0.248
	Housewife	4 (1.5)	269 (98.5)		
	Merchant	2 (6.5)	29 (93.5)		

	Unemployed	1 (2.8)	35 (97.2)		
	Others	1 (8.3)	11 (91.7)		
Family Size	1-2	3 (3.8)	75 (96.2)	7.200	0.027*
	3-4	2 (0.7)	283 (99.3)		
	> 4	6 (4.5)	127 (95.5)		
Partner's HIV Status	Negative	5 (3.6)	133 (96.4)	4.332	0.115
	Positive	2 (0.8)	242 (99.2)		
	Unknown	4 (3.5)	110 (96.5)		
Receiving regular supplies of ART	No	2 (4.9)	39 (95.1)	1.459	0.227
	Yes	9 (2.0)	446 (98.0)		
Level of Adherence	Poor	1(9.1)	10 (90.9)	18.553	<0.001*
	Fair	3 (15.0)	17 (85.0)		
	Good	7 (1.5)	458 (98.5)		
Opportunistic infection	Yes	5 (14.3)	30 (85.7)	25.290	<0.001*
	No	6 (1.3)	455 (98.7)		
WHO clinical stage	Stage II & III	5 (14.3)	30 (85.7)	25.290	<0.001*
	Stage I	6 (1.3)	455 (98.7)		
Alcohol/substance use in the last one month	Yes	3 (5.7)	50 (94.3)	3.243	0.072
	No	8 (1.8)	435 (98.2)		
HIV status disclosure other than HCWs	No	6 (4.5)	127 (95.5)	4.408	0.036*
	Yes	5 (1.4)	358 (98.6)		
The habit of using a memory aid	No	5 (2.6)	187 (97.4)	0.216	0.642
	Yes	6 (2.0)	298 (98.0)		
Previous ART regimen	1B	0 (0.0)	2 (100.0)	2.173	0.537
	1C (AZT + 3TC + NVP)	0 (0.0)	34 (100.0)		
	1E (TDF + 3TC + EFV)	6 (1.9)	314 (98.1)		
ART duration	6-11 months	2 (3.8)	51 (96.2)	0.753	0.861
	1 to 5 years	4 (2.3)	171 (97.7)		
	5 to 10 years	3 (1.8)	162 (98.2)		
	more than 10 years	2 (1.9)	101 (98.1)		
Type of participants	Pregnant	4 (2.3)	172 (97.7)	0.004	0.951
	Lactating	7 (2.2)	313 (97.8)		
Gestational Age (n=176)	First Trimester	0 (0.0)	11 (100.0)	4.483	0.106
	Second Trimester	0 (0.0)	81 (100.0)		
	Third Trimester	4 (4.8)	80 (95.2)		
Gravidity	Primigravida	4 (2.1)	190 (97.9)	0.036	0.850
	Multigravida	7 (2.3)	295 (97.7)		
Parity	0-1 child	7 (1.9)	355 (98.1)	0.499	0.480
	>=2 child	4 (3.0)	130 (97.0)		
MUAC	<23 cm	1 (4.3)	22 (95.7)	0.505	0.477
	>=23 cm	10 (2.1)	463 (97.9)		
CD4	<350 cells/ul	4 (12.1)	29 (87.9)	15.989	<0.001*
	>=350	7 (1.5)	456 (98.5)		
Syphilis Antibody test	Positive	1 (7.1)	13 (92.9)	1.611	0.204
	Negative	10 (2.1)	472 (97.9)		

576 *indicates p-value less than <0.05

577

578

579

580 **Table 5: Mann-Whitney U analysis of quantitative variables distribution among**
581 **PMTCT Mothers**

Quantitative variables	HIV-1 Viral Non-suppressed (N=11)	HIV-1 Viral Suppressed (N=485)	P- value
Age, Median (IQR)	35 (30, 37)	30 (27, 35)	0.075
Duration on ART in months, Median (IQR)	60 (15.5, 120)	72 (28, 120)	0.696
MUAC measurement in cm, Median (IQR)	25 (23, 25.53)	25 (24, 26)	0.396
CD4 T cell in cells/ul, Median (IQR)	548 (278, 555)	555 (542, 563)	0.013*
Heamoglobin in g/dl, Median (IQR)	12.87 (12.2, 12.92)	12.88 (12.2, 13.5)	0.408

582 *indicates the significance level <0.05

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598


599

600

601


602

603 **Figures**




604
605
606 **Figure 1: Proportion of participant's reason to stop/skip ART drugs within the last 6**
607 **months (n=211)**

608




609
610 **Figure 2: Proportions of ART drug regimen usage among PMTCT Mothers**

611



612


613 **Figure 3: Magnitude of HIV-1 non-suppression and Viral detectability among PMTCT**
 614 **Mothers**



615


616 *LLV: low-level viremia, ND: non-detectable*

617 **Figure 4: Distribution of low-level viremia, viral non-suppression and viral detectability**
 618 **among PMTCT Mothers**



619

620 **Figure 5: Sunkey diagram of the reason for SKIP/Missed ART drugs and distribution**
 621 **of viral non-suppression among PMTCT Mothers.**



622

623 *MUAC: Middle upper circumference, CD4: Cluster cell differentiation, Hgb: Haemoglobin*

624 **Figure 6: Mean distributions of Quantitative variables in non-suppressed and**
 625 **suppressed PMTCT Mothers**